# Request of endocrinology and metabolism journals for data sharing statements in clinical trial reports: a survey

**Authors:** Yingxin Liu, Bo Chen, Jingyi Zhang, Xuerui Bai, Lili Kang, Wenli Li, Guowei Li

PMC · DOI: 10.3389/fmed.2025.1518399 · Frontiers in Medicine · 2025-05-21

## TL;DR

This study examines whether endocrinology and metabolism journals require data sharing statements in clinical trial reports and finds inconsistencies in their practices.

## Contribution

The study reveals that a significant proportion of endocrinology and metabolism journals do not consistently request or publish data sharing statements in clinical trial reports.

## Key findings

- 88.7% of endocrinology and metabolism journals requested data sharing statements in clinical trial submissions.
- 15.6% of journals that requested data sharing statements did not include them in published trial reports.
- Journals requesting data sharing statements had lower JCR quartiles and higher impact factors.

## Abstract

To enhance reproducibility and transparency, the International Committee of Medical Journal Editors (ICMJE) required that all trial reports submitted after July 2018 must include a data sharing statement (DSS). Accordingly, emerging biomedical journals required trial authors to include a DSS in submissions for publication if trial reports were accepted. Nevertheless, it was unclear whether endocrinology and metabolism journals had this request for DSS of clinical trial reports. Therefore, we aimed to explore whether endocrinology and metabolism journals requested DSS in clinical trial submissions, and their compliance with the declared request in published trial reports.

Journals that were from the category of “Endocrinology & Metabolism” defined by Journal Citation Reports (JCR, as of June 2023) and published clinical trial reports between 2019 and 2022, were included for analysis. The primary outcome was whether a journal explicitly requested a DSS in its manuscript submission instructions for clinical trials, which was extracted and verified in December 2023. We also evaluated whether these journals indeed included a DSS in their published trial reports that were published between December 2023 and May 2024.

A total of 141 endocrinology and metabolism journals were included for analysis, among which 125 (88.7%) requested DSS in clinical trial submissions. Journals requesting DSS had a significantly lower JCR quartile and higher impact factor when compared with those journals without DSS request. Among the 90 journals requesting DSS, 14 (15.6%) journals indeed did not publish any DSS in their published trial reports between December 2023 and May 2024.

Over 10% of endocrinology and metabolism journals did not request DSS in clinical trial submissions. More than 15% of the journals declaring to request DSS from their submission instructions, did not publish DSS in their published trial reports. More efforts are needed to improve the practice of endocrinology and metabolism journals in requesting and publishing DSS of clinical trial reports.

## Full-text entities

- **Diseases:** metabolic diseases (MESH:D008659), DSS (MESH:D012753), endocrine and metabolic disorders (MESH:D004700), type 2 diabetes mellitus (MESH:D003924)
- **Chemicals:** DSS (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12133921/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12133921/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC12133921/full.md

---
Source: https://tomesphere.com/paper/PMC12133921